Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6-35 Months
Latest Information Update: 05 Mar 2019
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
- 05 Mar 2019 New trial record